



# Melinta Therapeutics to Present at BioCentury Future Leaders Conference

NEW HAVEN, Conn., March 03, 2016 -- [Melinta Therapeutics](#) today announced that Dr. Eugene Sun, the Company's interim Chief Executive Officer, will present a clinical and corporate update at BioCentury's 23rd annual Future Leaders in the Biotech Industry conference at 11:30 a.m. ET on March 11, 2016. The conference is being held at the Millennium Broadway Hotel & Conference Center in New York City, NY.

The Future Leaders in the Biotech Industry conference connects Wall Street and pharmaceutical executives with private and public biotechnology companies, offering new investment and partnering opportunities. Last year, more than 500 delegates, representing top financial institutions, pharmaceutical business development executives, and high net worth investors congregated at Future Leaders. For more information, or to request a one-on-one meeting with Melinta, please visit: <http://www.biocentury.com>.

## About Melinta Therapeutics

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development of novel antibiotics that provide new and better therapeutic solutions. Melinta is rapidly progressing its late-stage investigational antibiotic, Baxdela, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Melinta is committed to developing, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Enterobacter* species and *Escherichia coli*), which cause the majority of life-threatening hospital infections.

Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners ([www.vaterahealthcare.com](http://www.vaterahealthcare.com)) and Malin Corporation plc ([www.malinplc.com](http://www.malinplc.com)) among other private investors. The company is headquartered in New Haven, CT with offices in Lincolnshire, IL. Visit [www.melinta.com](http://www.melinta.com) for more information.

Melinta Therapeutics  
Kathy Powell  
(312) 724-9400  
[news@melinta.com](mailto:news@melinta.com)

Media Contact  
Aline Sherwood  
(312) 238-8957  
[asherwood@scientapr.com](mailto:asherwood@scientapr.com)